InMode Ltd. (NASDAQ:INMD) Receives Average Rating of "Hold" from Analysts

Key Points

• InMode Ltd. has received an average rating of "Hold" from analysts, with one sell rating, eight hold ratings, and one buy rating among the ten ratings firms covering the company.
• The firm's average 1-year target price is $16.85, with recent price adjustments ranging from $14.00 to $24.00 by different analysts.
• InMode's latest earnings report showed $0.47 EPS, missing expectations of $0.50 EPS, and revenue of $95.60 million, below the anticipated $98.45 million.

InMode Ltd. (NASDAQ:INMD - Get Free Report) has earned an average recommendation of "Hold" from the ten ratings firms that are covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and one has given a buy rating to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $16.85.

Several analysts recently weighed in on the stock. Weiss Ratings reaffirmed a "sell (d+)" rating on shares of InMode in a report on Wednesday, October 8th. Needham & Company LLC reaffirmed a "hold" rating on shares of InMode in a report on Friday, October 10th. Wall Street Zen raised shares of InMode from a "hold" rating to a "buy" rating in a report on Saturday. Canaccord Genuity Group raised their target price on shares of InMode from $14.00 to $16.00 and gave the company a "hold" rating in a report on Friday, October 10th. Finally, Barclays reduced their target price on shares of InMode from $24.00 to $21.00 and set an "overweight" rating on the stock in a report on Wednesday, July 30th.

Institutional Trading of InMode

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in INMD. Oppenheimer Asset Management Inc. acquired a new stake in InMode during the first quarter worth approximately $204,000. Kirr Marbach & Co. LLC IN raised its holdings in InMode by 9.4% during the first quarter. Kirr Marbach & Co. LLC IN now owns 88,625 shares of the healthcare company's stock worth $1,572,000 after purchasing an additional 7,601 shares in the last quarter. Bessemer Group Inc. acquired a new stake in InMode during the first quarter worth approximately $617,000. Allspring Global Investments Holdings LLC acquired a new stake in InMode during the first quarter worth approximately $192,000. Finally, Marathon Asset Management Ltd raised its holdings in InMode by 2.7% during the first quarter. Marathon Asset Management Ltd now owns 187,259 shares of the healthcare company's stock worth $3,322,000 after purchasing an additional 4,910 shares in the last quarter. Institutional investors and hedge funds own 68.04% of the company's stock.

InMode Price Performance

Shares of InMode stock opened at $15.31 on Monday. The business has a 50-day moving average of $14.89 and a 200 day moving average of $14.65. InMode has a 12 month low of $13.14 and a 12 month high of $19.85. The stock has a market capitalization of $967.75 million, a price-to-earnings ratio of 6.20 and a beta of 2.09.

InMode (NASDAQ:INMD - Get Free Report) last announced its earnings results on Wednesday, July 30th. The healthcare company reported $0.47 EPS for the quarter, missing analysts' consensus estimates of $0.50 by ($0.03). InMode had a net margin of 44.50% and a return on equity of 18.38%. The firm had revenue of $95.60 million for the quarter, compared to analysts' expectations of $98.45 million. During the same quarter last year, the business earned $0.34 earnings per share. The business's revenue was up 10.6% compared to the same quarter last year. Equities research analysts anticipate that InMode will post 1.75 earnings per share for the current year.

About InMode

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.